1、Infusion ServicesSECTOR SPOTLIGHTWIN TER 2023 New Indications Expanding Infusion UtilizationNew indications will continue to expand the addressable population that can be treated with infusible drugs Immunology Shows Greatest U.S.Growth3Long-Term,Macro Value Drivers in InfusionPipeline of Infusible

2、Drugs and Biosimilars460%of therapies in front of the FDA for approval are infusible,driving growth to alternate sites as payors seek more affordable and convenient care settingsAttractive Reimbursement Outlook 6Due to the cost benefits associated with alternate site infusion therapy,the reimburseme

3、nt outlook remains favorable as payors continue to create incentives to drive care out of the hospitalHome+AIC Is the Winning Model5Investor sentiment strongly weighted toward a long-term strategy that includes both home and AICs$-$10$20$30$40$5020192020E2021E2022E2023E2024ESavings Range High/LowSav

4、ings Base CaseKey inflection point as biosimilars continue to get approved and launch,including introduction of Biosimilar Red Tape Elimination ActSource:BCG,IQVIA,industry estimates.(1)Includes blended average of physician office and AIC.(2)Based on survey of combined 27,600 members of three major

5、payor networks.Physician Awareness and Patient Preference for Alternative Sites of Care 2Increased physician awareness and comfort with infusions taking place in alternative sites are compounded(post-pandemic)by patient preference and improved patient outcomes and adherence 64%60%10%7%23%35%29%17%55

6、%MACommercialCurrent InfusionMarketHomeOffice/AmbulatoryHospitalPatient Preference,by Site of Infusion(2)Biosimilar Spend in BillionsShift of Care Shift1Payor-,physician-,and patient-driven tailwinds continue to drive the site of care for infusion out of the hospital and into alternate sitesAverage